Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLEEVEC-RESISTANT LEUKEMIA, CONTAINING, AS ACTIVE INGREDIENT, GINSENOSIDE F1 OR RG3
Document Type and Number:
WIPO Patent Application WO/2016/178510
Kind Code:
A3
Abstract:
The present invention relates to: a pharmaceutical composition for preventing or treating Gleevec-resistant leukemia, containing, as an active ingredient, ginsenoside F1 or Rg3 which exhibits a preventive or treatment effect on Gleevec-resistant leukemia; a method for treating Gleevec-resistant leukemia comprising a step of administering the pharmaceutical composition; and a food composition for preventing or alleviating Gleevec-resistant leukemia. When using the pharmaceutical composition of the present invention, leukemia exhibiting resistance due to conventional Gleevec can be effectively treated, and thus the pharmaceutical composition can be widely used for effective leukemia treatment.
More Like This:
Inventors:
KIM SUN CHANG (KR)
KIM HUN SIK (KR)
KIM HUN SIK (KR)
Application Number:
PCT/KR2016/004699
Publication Date:
December 29, 2016
Filing Date:
May 04, 2016
Export Citation:
Assignee:
INTELLIGENT SYNTHETIC BIOLOGY CT (KR)
International Classes:
A61K31/704; A61K31/506; A61K31/70; A61K45/06
Other References:
CHOI, C.-H. ET AL.: "Reversal of P-glycoprotein-mediated Multidrug Resistance by Protopanaxatriol Ginsenosides from Korean Red Ginseng", PLANT A MEDICA, vol. 69, no. 3, 2003, pages 235 - 240, XP008029980
HASEGAWA, H. ET AL.: "Reveisal of Daunomycin and Vinblastine Resistance in Multidrug-iesistant P388 Leukemia in Vitro through Enhanced Cytotoxicity by Triterpenoids", PLANTA MEDICA, vol. 61, no. 5, 1995, pages 409 - 413, XP001119242
HOU, Y. ET AL.: "Ginseng Extract Enhances Anti-cancer Effect of Cytarabine on Human Acute Leukemia Cells", ADVANCE JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 7, no. 3, 5 February 2015 (2015-02-05), pages 164 - 168, XP009501719
KWON, H.-Y. ET AL.: "Selective Toxicity of Ginsenoside Rg3 on Multidrug Resistant Cells by Membrane Fluidity Modulation", ARCH. PHARM. RES., vol. 31, no. 2, 2008, pages 171 - 177, XP053007308
KIM, S. -W. ET AL.: "Reversal of P-glycoprotein-mediated Multidrug Resistance by Ginsenoside Rg3", BIOCHEMICAL PHARMACOLOGY, vol. 65, 2003, pages 75 - 82, XP055340547
See also references of EP 3181137A4
HASEGAWA, H. ET AL.: "Reveisal of Daunomycin and Vinblastine Resistance in Multidrug-iesistant P388 Leukemia in Vitro through Enhanced Cytotoxicity by Triterpenoids", PLANTA MEDICA, vol. 61, no. 5, 1995, pages 409 - 413, XP001119242
HOU, Y. ET AL.: "Ginseng Extract Enhances Anti-cancer Effect of Cytarabine on Human Acute Leukemia Cells", ADVANCE JOURNAL OF FOOD SCIENCE AND TECHNOLOGY, vol. 7, no. 3, 5 February 2015 (2015-02-05), pages 164 - 168, XP009501719
KWON, H.-Y. ET AL.: "Selective Toxicity of Ginsenoside Rg3 on Multidrug Resistant Cells by Membrane Fluidity Modulation", ARCH. PHARM. RES., vol. 31, no. 2, 2008, pages 171 - 177, XP053007308
KIM, S. -W. ET AL.: "Reversal of P-glycoprotein-mediated Multidrug Resistance by Ginsenoside Rg3", BIOCHEMICAL PHARMACOLOGY, vol. 65, 2003, pages 75 - 82, XP055340547
See also references of EP 3181137A4
Attorney, Agent or Firm:
SON, Min (6th Floor 163, YangJaeCheon-ro,,Gangnam-gu, Seoul, KR)
Download PDF: